Nippon Chemiphar Co., Ltd.

Tokyo Stock Exchange 4539.T

Nippon Chemiphar Co., Ltd. EBITDA for the year ending March 31, 2024: USD 9.27 M

Nippon Chemiphar Co., Ltd. EBITDA is USD 9.27 M for the year ending March 31, 2024, a -2.26% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Nippon Chemiphar Co., Ltd. EBITDA for the year ending March 31, 2023 was USD 9.48 M, a -52.14% change year over year.
  • Nippon Chemiphar Co., Ltd. EBITDA for the year ending March 31, 2022 was USD 19.81 M, a 12.07% change year over year.
  • Nippon Chemiphar Co., Ltd. EBITDA for the year ending March 31, 2021 was USD 17.68 M, a 16.15% change year over year.
  • Nippon Chemiphar Co., Ltd. EBITDA for the year ending March 31, 2020 was USD 15.22 M, a -39.91% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
Tokyo Stock Exchange: 4539.T

Nippon Chemiphar Co., Ltd.

CEO Mr. Kazushiro Yamaguchi
IPO Date Jan. 1, 2001
Location Japan
Headquarters 2-2-3, Iwamoto-cho
Employees 887
Sector Health Care
Industries
Description

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.

Similar companies

4521.T

Kaken Pharmaceutical Co., Ltd.

USD 26.94

-0.58%

4553.T

Towa Pharmaceutical Co., Ltd.

USD 20.75

-0.79%

4506.T

Sumitomo Pharma Co., Ltd.

USD 3.49

1.85%

4516.T

Nippon Shinyaku Co., Ltd.

USD 24.53

-2.23%

StockViz Staff

January 16, 2025

Any question? Send us an email